Caov-3 Cells

Caov-3 cells are derived from the ovary of a 54-year-old Caucasian woman with adenocarcinoma, provide researchers with a representative model for high-grade ovarian cancer. The cell line was established in 1976 and has since been used in numerous studies.
With their epithelial morphology, Caov-3 cells closely resemble the characteristics of primary ovarian cancer cells. When cultured, these cells form densely packed colonies that mimic the behavior observed in the human body. Their unique properties make them an ideal choice for researchers studying the growth, behavior and response of ovarian cancer cells.
An important finding in this field is the effect of all-trans retinoic acid on Caov-3 cells. Studies have shown that this compound suppresses the growth of these ovarian cancer cells in vitro. In addition, Caov-3 cells express various tumor-associated antigens, including NB/70K, CA-125, Ba-2, and Ca-1, which increases their utility for research into targeted therapies and immunotherapies.
The genome of Caov-3 cells exhibits significant abnormalities explaining their tumorigenic properties. For example, these cells have a nonsense mutation in the p53 tumor suppressor gene and possess multiple copies of the ovarian cancer oncogene PIK3CA, which plays a critical role in cancer development and progression. In terms of drug sensitivity, Caov-3 cells respond to several commonly used chemotherapeutic agents.
Vinblastine, cisplatin and adriamycin have been shown to have an effect on these cells. Another characteristic of Caov-3 cells is their behavior under different culture conditions. While these cells do not grow in soft agar, they exhibit tumorigenic properties when injected into immunocompromised mice. Therefore, among their many applications in research, Caov-3 cells are particularly suitable for 3D cell culture experiments.
Due to their epithelial morphology and ability to form dense colonies, they are the ideal choice for studying cell-cell interactions, tissue organization and behavior of ovarian cancer cells in a more physiologically relevant environment. However, the long doubling time of approximately 78 hours must be considered in experimental design.